Skip to main content
Publications
Herring WL , Gallagher ME, Shah N, Morse KC, Mladsi D , Dong OM , Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States . Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Hamadani M, Spira AI, Zhou X , Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial . Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Layton JB , Peetluk L, Wong HL, Jiao Y, Djibo DA, Bui C , Lloyd PC, Gruber JF, Miller M, Ogilvie RP, Deng J, Parambi R, Song J, Weatherby LB, Lo AC, Matuska K, Wernecke M, Clarke TC, Cho S, Bell EJ, Seeger JD, Yang GW, Illei D, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Amend KL, Anthony M , Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States . Vaccine-X. 2024 Jan;16:100447. doi: 10.1016/j.jvacx.2024.100447
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL , Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma . Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Ribera A, Marsal JR , Faixedas MT, Rosas A, Tizon-Marcos H, Rojas S, Labata C, Cardenas M, Homs S, Tomas-Querol C, Garcia-Picart J, Roura G, Masotti M, Mauri J, Pijoan JI, Barrabes JA, Ferreira-Gonzalez I, Codi IAM Investigators Investigators. Revascularized ST-segment elevation myocardial infarction. Temporal trends in contemporary therapies and impact on outcomes . Rev Esp Cardiol. 2022 Aug;75(8):659-68. doi: 10.1016/j.rec.2021.10.011.
Spelman T, Herring WL , Zhang Y, Tempest M, Pearson I , Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom . Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Ferreira-Gonzalez I, Permanyer Miralda G, Heras M, Ribera A, Marsal JR , Cascant P, Aros F, Bueno H, Sanchez PL, Cunat J, Civeira E, Marrugat J, Investigadores del Estudio MASCARA. Prognosis and management of patients with acute coronary syndrome and polyvascular disease . Rev Esp Cardiol. 2009 Sep;62(9):1012-21. doi: 10.1016/s1885-5857(09)73267-0
Ribera A, Ferreira-Gonzalez I, Cascant P, Marsal JR , Romero B, Pedrol D, Martinez-Useros C, Pons JM, Fernandez T, Permanyer-Miralda G, ARCA Study Investigators. Survival, clinical status and quality of life five years after coronary surgery. The ARCA study . Rev Esp Cardiol. 2009 Jun;62(6):642-51. doi: 10.1016/s1885-5857(09)72228-5